Stem cells

Global Cell Sorting Market 2019-2023 | Growing Applications in Cancer Research to Boost Growth | Technavio

Monday, June 1, 2020 - 10:15pm

Our cell sorting market report covers the following areas:

Key Points: 
  • Our cell sorting market report covers the following areas:
    This study identifies technological advances as one of the prime reasons driving the cell sorting market growth during the next few years.
  • We provide a detailed analysis of around 25 vendors operating in the Cell Sorting Market, including some of the vendors such as Becton, Dickinson, and Co., Bio-Rad Laboratories Inc., Cytonome/St.
  • Backed with competitive intelligence and benchmarking, our research reports on the Cell Sorting Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection

Monday, June 1, 2020 - 1:00pm

Proteona today announced that Twist Bioscience Corporation (Nasdaq: TWST) will join the international alliance led by Proteona to develop neutralizing antibody therapy against COVID-19 for vulnerable immunocompromised patients.

Key Points: 
  • Proteona today announced that Twist Bioscience Corporation (Nasdaq: TWST) will join the international alliance led by Proteona to develop neutralizing antibody therapy against COVID-19 for vulnerable immunocompromised patients.
  • The international alliance was initiated by Proteona in response to the urgent need of patients most at risk facing the pandemic, such as those with blood cancers.
  • The alliance aims to develop antibody therapies to provide a safe and targeted treatment for these vulnerable populations.
  • Twist Bioscience is an instrumental addition to the alliance, said Andreas Schmidt, CEO of Proteona.

Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy

Monday, June 1, 2020 - 1:00pm

The loss of retina pigmented epithelium (RPE) cells over time creates progressively larger areas of atrophy in the adult retina, leading to impaired vision or complete blindness, a condition known as dry AMD.

Key Points: 
  • The loss of retina pigmented epithelium (RPE) cells over time creates progressively larger areas of atrophy in the adult retina, leading to impaired vision or complete blindness, a condition known as dry AMD.
  • The unique finding from the ongoing OpRegen clinical trial supports a different view, in which an RPE cell transplant can potentially replace or rescue retinal cells in patients who suffer from retinal lesions or degeneration.
  • We report evidence from a patient with atrophic end-stage disease who received a transplant of allogeneic RPE cells and showed substantial restoration of retinal tissue within the area of GA.
  • Any therapy which can save photoreceptors and RPE cells in areas of geographic atrophy would be very important to these patients.

Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Friday, May 29, 2020 - 1:00pm

For 12 of the 13 patients, sufficient cells for all six planned doses were generated; two doses were available for the remaining patient.

Key Points: 
  • For 12 of the 13 patients, sufficient cells for all six planned doses were generated; two doses were available for the remaining patient.
  • As the tumor microenvironment varies from patient to patient, the ability to address these differences may offer a significant benefit to patients.
  • Unlike other cell therapies which require pre-conditioning regimens and hospitalization, MultiTAA is designed to be administered in an outpatient setting.
  • Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e.

AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A

Friday, May 29, 2020 - 1:00pm

Under the terms of the agreement, Sernova has been granted a time-limited, non-exclusive research license by AgeX.

Key Points: 
  • Under the terms of the agreement, Sernova has been granted a time-limited, non-exclusive research license by AgeX.
  • A commercial license for Sernova to utilize UniverCyte to engineer cellular products for therapeutic and commercial purposes may be negotiated between the companies pending successful study outcomes.
  • UniverCyte uses a novel, modified form of HLA-G, a potent immunomodulatory molecule, which in nature protects an unborn child from their mothers immune system.
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

Geron Corporation Reports First Quarter 2020 Financial Results

Thursday, May 28, 2020 - 9:05pm

MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020.

Key Points: 
  • MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020.
  • As of March 31, 2020, Geron had approximately $133 million in cash, cash equivalents, and current and non-current marketable securities.
  • Revenues for the first quarter of 2020 were $52,000 compared to $57,000 for the comparable 2019 period.
  • Total operating expenses for the first quarter of 2020 were $16.9 million compared to $11.4 million for the comparable 2019 period.

ViaCyte to Present at the Jefferies Virtual Healthcare Conference

Thursday, May 28, 2020 - 2:00pm

SAN DIEGO, May 28, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9.

Key Points: 
  • SAN DIEGO, May 28, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9.
  • ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement.
  • During the presentation, Dr. Laikind will discuss ViaCyte's leadership in discovering and developing novel cell replacement therapies to treat human diseases.
  • With CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 pluripotent stem cell line.

StemExpress Expands Offering of COVID-19 Testing to Skilled Nursing Facilities

Thursday, May 28, 2020 - 10:00am

Testing services have now been expanded to skilled nursing facilities.

Key Points: 
  • Testing services have now been expanded to skilled nursing facilities.
  • The company has been working directly with the California Testing Task Force to offer testing to the general public and to specifically help skilled nursing facilities manage COVID-19 testing.
  • The nursing centers will use their licensed staff to collect specimens and send them to StemExpress high complexity CLIA laboratory for testing.
  • StemExpress multiple locations and specimen collection options will aid these vulnerable facilities to provide fast and high quality COVID-19 testing to their employees and residents.

Frequency Therapeutics to Present at Upcoming Investor Conferences

Wednesday, May 27, 2020 - 1:00pm

A replay of each presentation will be posted on the Frequency website for at least 30 days following each event.

Key Points: 
  • A replay of each presentation will be posted on the Frequency website for at least 30 days following each event.
  • Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases.
  • The Companys progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies.
  • The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.

WindMIL Therapeutics to Present at Jefferies Virtual Healthcare Conference 2020

Wednesday, May 27, 2020 - 12:00pm

PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.

Key Points: 
  • PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.
  • WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy.
  • As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients.
  • The companys proprietary process to activate, transform and expand T cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence.